|Bid||2.39 x 900|
|Ask||2.42 x 200|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 30, 2017 - Mar 31, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.75|
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Argos ...
Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc. (NASDAQ: ITCI), Argos Therapeutics Inc. (NASDAQ: ARGS), Array BioPharma Inc. (NASDAQ: ARRY), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH).
Case in point: Argos Therapeutics (NASDAQ:ARGS) shares are tanking nearly 64% in Tuesday's trading session, after the drug maker reported disappointing interim results from its Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of newly diagnosed metastatic renal cell carcinoma. After consulting with the principal investigators of the trial, the Company has therefore decided to discontinue the trial. As previously reported, a total of 462 patients with previously untreated advanced or metastatic renal cell carcinoma were enrolled in the ADAPT trial and randomized 2:1 between combination treatment with Rocapuldencel-T and sunitinib (combination arm) vs. sunitinib monotherapy (control arm) after undergoing cytoreductive nephrectomy.
Stock Monitor: Argos Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on Alexion Pharma, Inc. (NASDAQ: ALXN ...
NEW YORK, NY / ACCESSWIRE / April 12, 2018 / U.S. markets fell sharply on Wednesday on growing geopolitical tensions. On Wednesday President Trump tweeted, "Russia vows to shoot down any and all missiles ...
The Durham, North Carolina-based company said it had a loss of 38 cents per share. Losses, adjusted for non-recurring gains and to extinguish debt, came to $1.05 per share. The biotechnology company posted ...
To paraphrase an old love song: what a difference a week makes , and that difference is fear. I would be lying if the recent correction in the market didn’t catch me off guard. Since the rest of the market ...
NEW YORK, NY / ACCESSWIRE / February 7, 2017 / U.S. markets experienced a volatile day of trading Tuesday, but managed to snap the streak of two consecutive days of steep selloffs. The Dow Jones Industrial ...
After reading Argos Therapeutics Inc’s (NASDAQ:ARGS) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past andRead More...
On the heels of Argos Therapeutics (ARGS) executing a one-for-twenty reverse stock split , another Durham-based biopharmaceutical company Heat Biologics (HTBX) has undertaken a one-for-ten reverse stock split of its own. Last year, Heat outlined a new strategy moving forward, focused on combination therapies for the treatment of cancer .
Durham’s Argos Therapeutics (ARGS) has executed a one-for-twenty reverse stock split as well as a move from The Nasdaq Global Market to The Nasdaq Capital Market. Shares of Argos had remained under $1 for the better part of 2017, after a significant drop at the beginning of last year. The drop came in conjunction with an independent data monitoring committee’s recommendation that Argos discontinue its Phase 3 trial of lead product candidate Rocapuldencel-T – for the treatment of metastatic kidney cancer – sinking the company’s stock price more than 65 percent .
Jeff Abbey has been at the helm as CEO of Argos Therapeutics Inc (NASDAQ:ARGS), which has grown to a market capitalization of $13.62M. Understanding how CEOs are incentivised to runRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Argos Therapeutics, Inc. Here are 5 ETFs with the largest exposure to ARGS-US. Comparing the performance and risk of Argos Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
If you are looking to invest in Argos Therapeutics Inc’s (NASDAQ:ARGS), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...